<DOC>
	<DOCNO>NCT01724788</DOCNO>
	<brief_summary>Primary Objective : - To determine absolute bioavailability furosemide 500 mg ( Lasix® Special ) oral formulation patient chronic renal failure undergo peritoneal dialysis . Secondary Objectives : - To determine pharmacokinetic profile furosemide 500 mg ( Lasix® Special ) oral formulation 250 mg IV formulation - To compare pharmacodynamic characteristic furosemide 500 mg ( Lasix® Special ) oral formulation 250 mg IV formulation</brief_summary>
	<brief_title>Pharmacokinetic Profile Pharmacodynamic Characteristics Furosemide High Dosage Formulation Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis</brief_title>
	<detailed_description>- Screening : 7 10 day - Treatment period : 14 day ( Period 1 : 7 day ; Period 2 : 7 day ) - End study : 7 day last dosing , - Total duration screen per subject : 22 25 day .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Inclusion criterion : Male female , 18 year old old , chronic renal failure undergo peritoneal dialysis least 3 month . Women childbearing age negative pregnancy test administration study drug Exclusion criterion : Contraindications furosemide , include : Hypersensitivity furosemide sulphonamidederived drug ingredient formulation component container . Glomerular filtration rate 5 mL/min Glomerular filtration rate 20 mL/min Severe liver disease Patients renal failure accompany hepatic coma precoma Renal failure due poisoning nephrotoxic hepatotoxic substance Severe hyponatremia , hypokalemia , hypovolemia , dehydration hypotension Nursing woman Pregnancy Treatment diuretic , discontinue require washout period first drug administration Existence surgical medical condition , , judgment clinical investigator , might interfere absorption , distribution , metabolism excretion drug . Psychiatric cognitive disturbance illness , recreational drug/alcohol use , opinion principal investigator , would affect patient safety and/or compliance . Treatment follow inhibitor secretion renal level : clarithromycin , erythromycin , itraconazole , cyclosporin , ketoconazole , quinidine , verapamil , discontinue course study . Interfering substance : Subjects must abstain alcohol beverage contain stimulate xanthine derivates ( e.g . coffee tea ) entire study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>